Dynavax Technologies is a biopharmaceutical company dedicated to developing and commercializing novel vaccines to protect against infectious diseases. The company boasts a management team comprised of industry veterans with extensive experience in drug development and commercialization. With a rich knowledge-base acquired from successful biopharmaceutical companies and government organizations, the team leads a growing, fast-paced company.

Dynavax offers a unique product called HEPLISAV-B®, a differentiated hepatitis B vaccine that has received approval and is being commercialized. In addition, the company utilizes its proprietary CpG 1018® adjuvant to develop multiple COVID-19 vaccines and advance a diversified vaccine candidate pipeline. The brand has a range of experienced executives leading various departments, including a Chief Executive Officer, President, Chief Medical Officer, Chief Financial Officer, Chief Human Resources Officer, Chief Commercial Officer, and several Vice Presidents overseeing important areas such as clinical development, technical operations, business development, regulatory affairs, and more.

Overall, Dynavax is committed to protecting the world against infectious diseases through innovative vaccine development and commercialization